Compare Amylx Pharmaceuticals Inc (AMLX) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Indonesia Energy Corporation Limited — how do they compare? Amylx Pharmaceuticals Inc trades at $23.72 (market cap $2.64B), while Indonesia Energy Corporation Limited trades at $2.88 (market cap $45.55M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 58× Indonesia Energy Corporation Limited's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| AMLX | INDO | |
|---|---|---|
Market Cap | $2.64B | $45.55M |
Sector | Health | Energy |
52-Week High | $24.19 | $6.74 |
52-Week Low | $7.82 | $2.49 |
Enterprise Value | $2.39B | $40.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Indonesia Energy Corporation (INDO) trades at $2.89, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company is actively drilling the K-29 well at its Kruh Block, indicating operational progress. Financially, it shows deep losses with a net income margin of -253.4% and negative ROE of -26.95% for 2025, though it beat EPS estimates in Q2 2025. Valuation metrics include a P/S of 21.57 and P/B of 2.32, reflecting high sales multiples amid profitability challenges.
The outlook hinges on successful well outcomes driving future revenue; current analyst consensus is 100% buy, but high execution risks and persistent losses pose significant threats to shareholder value. Investors face volatility from oil price swings and operational delays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
